Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

National Advertising Division In Brief

This article was originally published in The Tan Sheet

Executive Summary

Firm complies with FTC testimonial guidance: Health King Enterprise & Balanceuticals Group Inc. discontinues a testimonial of atypical results for JointFlexer, even though it included a disclaimer, because Federal Trade Commission guidance dictates ads must express typical results, according to a May 20 release from the National Advertising Division (1"The Tan Sheet" Oct. 12, 2009). The Council of Better Business Bureaus division also recommended that Health King distinguish when claims apply to the overall supplement or to specific ingredients. NAD suggested the Chicago firm clarify claims - such as "promotes absorption of calcium and effectively inhibits joint degeneration" - are based on ingredient studies because "there is no research on the product," only on the individual ingredients. Similarly, NAD recommended the firm clarify the claim "used for centuries, proven by clinical trials and research in China" applies to herbal ingredients in JointFlexer and not the product or other ingredients. NAD also recommended the firm increase the dose of glucosamine from 1,125 mg daily to at least the minimum effective daily dose of 1,200 mg or discontinue claims linked to the ingredient

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104158

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel